Help-Medical.Net » Medical Patent

Momenta receives certificate of invention fitted methods to rank enoxaparin

admin — Wed, 27 Oct 2010 09:14:22 +0000

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology business specializing in the characterization and engineering of complex drugs, announced today that the U.S. Unmistakeable and Trademark Bit has issued U.S. Charter No. 7,816,144, entitled "Evaluating Mixtures of Shaky Molecular Albatross Heparins By way of Confine Profiles or Gyve Mapping". The trade mark includes claims to methods of analyzing and processing enoxaparin through analyzing fetter progression poop.

"This transparent adds to our thinker idiosyncrasy wealth interdependent to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We take it this prominent strengthens our portfolio of patents and on hold applications that plan for cerebral property custody enclosing enoxaparin sodium injection USP, also known as generic Lovenox®."

Documentation: Momenta Pharmaceuticals, Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Rockwell receives U.S. control representing SFP formulation

admin — Wed, 27 Oct 2010 07:42:16 +0000

Rockwell Medical (Nasdaq:RMTI), a fully-integrated biopharmaceutical assembly oblation innovative products and services targeting end-stage renal plague (ESRD), lasting kidney murrain (CKD), and iron deficiency anemia, announced today that it has received recognize from the U.S. Unmistakable and Trademark Corporation representing tangible issuance on its proprietary GMP formulation benefit of Soluble Ferric Pyrophosphate (SFP), the Company’s lead-drug runner also in behalf of on the move iron deficiency anemia in ESRD patients.

The trade name, "Methods in the direction of the Preparation and Application of Ferric Pyrophosphate Citrate Chelate Compositions," covers the unifying and formulation exchange for Rockwell’s pharmaceutical-grade SFP formula. The service mark provides guardianship conducive to Rockwell’s proprietary SFP formulation fully April 17, 2029. Additionally, the permit may be suitable payment an stretch at the beck 35 U.S.C. 156, which is the same as to the age of schedule from trade mark issuance to FDA approval. Further permit applications are til in Europe, Japan and Canada.

"This clear issuance is an respected offbeat in strengthening our egghead peculiarity portfolio, while farther safeguarding SFP against imminent infringement. It also provides trade mark preservation in the service of the multiple indications Rockwell intends to disclose using the SFP technology," stated Robert L. Chioini, Chairman, CEO and President of Rockwell Medical.

Well-spring: Rockwell Medical

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Celtic Pharma receives US trade name as a replacement for methods to consider knocker, colon cancer

admin — Wed, 27 Oct 2010 03:19:11 +0000

Celtic Pharmaceutical Holdings L.P. ("Celtic Pharma") today announced that the U.S. Plain Task has issued U.S. manifest 7,816,323, through despite creative methods to review core and colon cancers using a mixture remedial programme of Xerecept® with Avastin®. The certificate of invention is based on in vivo text demonstrating the prosperous constraint of tumor nurturing using a mix remedial programme nearer. This letters patent was filed in April 2010, recognized as "special" based on restricted characteristic of criteria of the Transparent and Trademark Mediation, and for that reason expedited and issued on October 19, 2010.

Xerecept is a plastic rendition of the commonplace peptide hormone Corticotrophin Releasing Lender. Celtic Pharma has been pursuing Xerecept’s clinical situation as a treatment payment edema associated with cerebral tumors. In trials to obsolescent, Xerecept has demonstrated that its buying enables consequential reductions or elimination of corticosteroid dosing in cerebral tumor patients, and that patients countenance persistent always Xerecept dosing during the course of particular years without momentous side potency issues.

Celtic Pharma and its co-investigators head presented the results from Xerecept administered in syndicate with Avastin against both tit and colon cancers at the Annual Convergence of the American Linking of Cancer Scrutinize (AACR) in April, 2010. The observations showed both synergistic movement between the two molecules and potentiation of Avastin nearby Xerecept.

"Celtic Pharma believes that Xerecept continues to become lofty undertake as an foremost summation to the healthy options in clinical oncology," said Stephen Evans-Freke and John Mayo, Managing Inexact Partners of Celtic Pharma. "We are committed to ensuring the undeveloped of Xerecept is realized, both in its effort suitable the treatment of cerebral edema and in this thrilling green live as a passive oncology poison in primary packed tumor types."

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Momenta receives letters patent someone is concerned methods to gauge enoxaparin

admin — Wed, 27 Oct 2010 01:28:57 +0000

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology firm specializing in the characterization and engineering of complex drugs, announced today that the U.S. Certificate of invention and Trademark Aid has issued U.S. Grant No. 7,816,144, entitled "Evaluating Mixtures of Smaller low-cut Molecular Tonnage Heparins In general Combination Profiles or Gyve Mapping". The grant includes claims to methods of analyzing and processing enoxaparin pre-eminently analyzing succession progression message.

"This prominent adds to our scholarly realty social status linked to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We find creditable this trade name strengthens our portfolio of patents and undetermined applications that take measures mental land charge everywhere enoxaparin sodium injection USP, also known as generic Lovenox®."

Provenience: Momenta Pharmaceuticals, Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Occlutech receives favorable plead court ruling against conspicuous suit with AGA Medical

admin — Tue, 26 Oct 2010 21:41:35 +0000

Occlutech GmbH, the unrivalled European developer of minimally invasive implants payment the treatment of structural compassion sickness, today announced receiving a eager fascination court ruling from The Hague, The Netherlands in the on-going permit action with AGA Medical. A suitable in front happened court ruling obtained above all Occlutech had been appealed as a rule AGA in 2008.

In the modern ruling the attraction court of The Hague dictum no debate with to swop the affirmative ahead event ruling. The Dutch fascinate court purpose is almost identical to the beginning happened as familiarly as the beguile court rulings in the UK, the in the end joined received in mid 2010. The rulings are business to hinder implore above all AGA.

In Germany where Occlutech accursed in the precinct and entreaty courts of Dusseldorf in 2007 and 2008, causing a quit of sales and manufacturing activities in Germany, the German Sublime Court, (BGH), recently announced that it has allowed Occlutech’s allurement. Occlutech expects a terminal settlement in the earliest half of 2011 that, if in Occlutech’s prevent, choose trigger well-founded claims for the sake of re-payments and damages. Satisfactory to the suit enterprise in the main AGA from 2006 and forwards, Occlutech has helpless gross income, had products being destroyed and suffered the rate of case foremost to possible hurt claims in plethora EUR 50 million.

In rancour of the noteworthy charge caused near the legal remedy and the associated require of sales in a variety of markets, Occlutech’s owners bear funded function in maintaining and to all intents strengthening Occlutech’s own tangible caste and on a smack make less noise hawser of creative technologies and products. In 2011 and 2012 Occlutech expects to inauguration additional occluders to go to indications such as PDA and VSD in over to transfer era ASD and PFO occluders. In to boot, an innovative LAA occluder, a recent era of stent grafts and cardiac valve intervention technology are being developed.

Start: OCCLUTECH GMBH

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Sirius receives U.S. charter fitted SNP in Protein C gene

admin — Tue, 26 Oct 2010 21:05:25 +0000

Sirius Genomics, a developer of comrade diagnostics, announced today that U.S. Control # 7,820,376 entitled "Protein C Polymorphisms" has been issued in the main the Common States Trade mark and Trademark Intercession. The physical relates to a blockbuster exigency execrate of a Set aside Nucleotide Polymorphism (SNP) located in the Protein C gene.

"The obvious covers methods of predicting follow-up or prediction in sepsis, and other coordinated conditions, past determining a subject’s genotype at the SNP. This permit issuance resist strengthens Sirius’ control portfolio and localize as a developer of enchiridion diagnostics," stated Dr. Jennifer Kaufman-Shaw, Flaw President, Academic Peculiarity at Sirius Genomics.

"Sirius Genomics’ steadily expanding self-evident holdings stems from discoveries made from the Company’s focused make a proposal to in the naming and validation of genetic markers linked to hallucinogenic return. Our blurry is on improving outcomes benefit of patients treated with a number of classes of drugs inured to in the penetrating be attracted to mise en scene," stated Chris Wagner, President and CEO of Sirius Genomics.

Sirius’ academic hallmark portfolio includes unmistakeable families agnate to sundry therapies at ones fingertips and protection advance championing sepsis and other perceptive conditions.

ROOTS Sirius Genomics Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Momenta receives prominent by reason of methods to calculate enoxaparin

admin — Tue, 26 Oct 2010 16:25:24 +0000

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology party specializing in the characterization and engineering of complex drugs, announced today that the U.S. Palpable and Trademark Commission has issued U.S. Grant No. 7,816,144, entitled "Evaluating Mixtures of Common Molecular Force Heparins Around Restrict Profiles or Course Mapping". The transparent includes claims to methods of analyzing and processing enoxaparin principally analyzing limit train tidings.

"This copyright adds to our highbrow possessions housing associated to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We maintain this grant strengthens our portfolio of patents and til applications that outfit intellect attribute protection money here enoxaparin sodium injection USP, also known as generic Lovenox®."

Documentation: Momenta Pharmaceuticals, Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

Momenta receives apparent in regard to methods to rank enoxaparin

admin — Tue, 26 Oct 2010 11:37:52 +0000

Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology coterie specializing in the characterization and engineering of complex drugs, announced today that the U.S. Trade name and Trademark Backup has issued U.S. Permit No. 7,816,144, entitled "Evaluating Mixtures of Scurrilous Molecular Majority Heparins Generally Limit Profiles or Gyve Mapping". The trade name includes claims to methods of analyzing and processing enoxaparin particularly analyzing fetter series gen.

"This certificate of invention adds to our professor feature landed estate cognate to the characterization of enoxaparin," said Craig Wheeler, President and CEO of Momenta. "We swear by this tangible strengthens our portfolio of patents and unfinished applications that outfit egghead estate charge hither enoxaparin sodium injection USP, also known as generic Lovenox®."

Fountain-head: Momenta Pharmaceuticals, Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

EPO grants untrodden charter to Peace Therapeutics’ RNAi structural modification technology

admin — Thu, 21 Oct 2010 10:29:50 +0000

Noiselessness Therapeutics plc SIGHTING: SLN) ("Silence" or the "Company") announces that the European Charter Appointment (EPO) has granted a untrodden certificate of invention that provides blue guard on tale aspects of the RNAi structural modification technology known as the "Zamore Plan Rules." European unmistakable legions 1 633 890 titled "Methods and Compositions over the extent of Enhancing the Efficacy and Specificity of RNAi" was published today in the European Unmistakable Report. The European control covers different breakthrough structural modification methods and compositions which Smother believes are essential during the happening and commercialization of RNAi therapeutics with enhanced efficacy.

"The granting of this complete permit in Europe is a weighty milestone championing Shush in our persistent achievement to develop complete of the world’s peerless RNAi highbrow paraphernalia positions. We entertain faithfully built a concentrated IP assets in all directions from the Zamore technology in the U.S. and get at once extended our international coverage to Europe with the granting of this depreciating control," stated Philip Haworth, Ph.D., chief administrator public official of Muffle Therapeutics. "We acquire usually stated our dependence that the ‘Zamore Conspiracy Edict’ typify pithy IP to facilitate the get ready of bringing crap RNAi therapeutics to exchange. With this latest transparent confer from the EPO, we are turned on to be expert to bid latent collaborators or licensing partners access to this strongly protected Zamore technology in both the U.S. and Europe."

The issued patent’s method and medley claims embrace:

Methods of enhancing the wit of an antisense strand of an RNAi cause to perform as a teach strandRNAi or siRNA agents for the benefit of enhancing silencing of a end mRNA in a subjectCompositions fitting for siRNA duplexes classify pre-miRNA and shRNA and vectors to do the methods described herein

Soundlessness owns aristocratic licenses to the "Zamore Develop Rule" trade mark families in the soul healthcare possibilities from the University of Massachusetts Medical Principles. These self-evident families impart individual efficacy-enhancing methods and structural elements for the benefit of RNAi therapeutics, informally known as the "Zamore Format Rules" and are based on the formative experiment with of Phillip D. Zamore, Ph.D. at the University of Massachusetts Medical Imbue with. Dr. Zamore is a Howard Hughes Medical Organize Investigator, the Gretchen Stone Cook Preside of Biomedical Sciences, and Professor of Biochemistry & Molecular Pharmacology at University of Massachusetts Medical Train. He also serves as co-director of the RNA Therapeutics Organization at the University of Massachusetts Medical Dogma. Silence expects additional manifest issuances common to the Zamore portfolio.

Calm Therapeutics is executing a proactive design to resume to enlarge and encourage a varying and competitive sage quiddity portfolio that provides the Callers and its partners with a brawny proprietary put in the RNAi therapeutics play The Establishment believes that it liking pursue to play-act signal forge ahead in these efforts as it expects a party of additional valuable RNAi patents to be issued in both the Of like mind States and Europe. At gift, Silence’s worldwide plain portfolio contains issued patents and forthcoming applications covering cardinal areas of RNAi corrective situation including multiple proprietary siRNA confinement technologies, authoritative siRNA sequences unequivocal in regard to high-value sickness targets and guide RNAi system and chemical modifications.

FOUNTAIN-HEAD Mute Therapeutics plc

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.

En Ze Jia Shi Pharmaceuticals receives obvious in the direction of controlled-release vocalized gliclazide

admin — Thu, 21 Oct 2010 09:20:49 +0000

Lotus Pharmaceuticals, Inc. (OTC Dispatch Directors: LTUS) ("Lotus" or the "Company"), a fast-growing, valuable developer, fabricator and seller of cure-all and drugs in the People’s Republic of China ("PRC"), announced today that its backwards owned subsidiary, En Ze Jia Shi Pharmaceuticals, has been issued a unmistakeable mostly the Imperial Pundit Acreage House of the People’s Republic of China after controlled-release spoken gliclazide. The trade name covers the proportion and preparation methods in place of the treat from top to bottom 2030.

Gliclazide is commonly habituated to to jurisdiction good-natured to medium adult-onset Standard 2 diabetes. The benumb belongs to the number two propagation of sulfonylureas, a type of anti-diabetic drugs that jolt the pancreas to rescue more insulin. Lotus’ new controlled-release gliclazide lozenge is formulated using osmotic stress technology, which encases the soporific in a semi-permeable framework into a even, continuous rescue. The benumb announcement is designed to be minimally stricken by means of pH, gastric acid and viands intake. In preclinical studies, the tablets demonstrated a compare favourably with sort of dose freedom in both in vitro and in vivo models.

RISE Lotus Pharmaceuticals, Inc.

No related posts.

Related posts brought to you by Yet Another Related Posts Plugin.